Connor, Clark & Lunn Investment Management (CC&L)’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-14,405
| Closed | -$177K | – | 1609 |
|
|
2023
Q2 | $177K | Buy |
+14,405
| New | +$177K | ﹤0.01% | 1204 |
|
|
2020
Q1 | – | Sell |
-107,098
| Closed | -$337K | – | 1248 |
|
|
2019
Q4 | $337K | Hold |
107,098
| – | – | ﹤0.01% | 737 |
|
|
2019
Q3 | $481K | Sell |
107,098
-90,982
| -46% | -$409K | ﹤0.01% | 692 |
|
|
2019
Q2 | $943K | Sell |
198,080
-7,535
| -4% | -$35.9K | 0.01% | 581 |
|
|
2019
Q1 | $1.12M | Sell |
205,615
-9,278
| -4% | -$50.7K | 0.01% | 505 |
|
|
2018
Q4 | $653K | Sell |
214,893
-3,178
| -1% | -$9.66K | ﹤0.01% | 643 |
|
|
2018
Q3 | $914K | Sell |
218,071
-4,067
| -2% | -$17K | 0.01% | 580 |
|
|
2018
Q2 | $858K | Buy |
222,138
+40,048
| +22% | +$155K | ﹤0.01% | 643 |
|
|
2018
Q1 | $1.15M | Buy |
182,090
+69,429
| +62% | +$440K | 0.01% | 463 |
|
|
2017
Q4 | $909K | Buy |
112,661
+67,176
| +148% | +$542K | 0.01% | 527 |
|
|
2017
Q3 | $520K | Buy |
45,485
+35,339
| +348% | +$404K | ﹤0.01% | 637 |
|
|
2017
Q2 | $99K | Buy |
+10,146
| New | +$99K | ﹤0.01% | 785 |
|
|
2016
Q3 | – | Sell |
-13,892
| Closed | -$589K | – | 962 |
|
|
2016
Q2 | $589K | Sell |
13,892
-48,412
| -78% | -$2.05M | ﹤0.01% | 556 |
|
|
2016
Q1 | $4.1M | Sell |
62,304
-49,023
| -44% | -$3.23M | 0.03% | 246 |
|
|
2015
Q4 | $6.92M | Sell |
111,327
-17,660
| -14% | -$1.1M | 0.06% | 177 |
|
|
2015
Q3 | $8.64M | Sell |
128,987
-1,367
| -1% | -$91.5K | 0.07% | 140 |
|
|
2015
Q2 | $12.7M | Sell |
130,354
-3,444
| -3% | -$335K | 0.12% | 96 |
|
|
2015
Q1 | $12.5M | Buy |
133,798
+39,795
| +42% | +$3.72M | 0.11% | 96 |
|
|
2014
Q4 | $8.36M | Buy |
94,003
+73,985
| +370% | +$6.58M | 0.07% | 122 |
|
|
2014
Q3 | $1.38M | Buy |
+20,018
| New | +$1.38M | 0.01% | 257 |
|